Beam Therapeutics is betting that a newer, more precise form of gene editing can fix genetic diseases without the DNA damage risks tied to older approaches. Early human results in a liver-targeted program, plus a push to remove harsh chemotherapy from stem cell transplants, could open much larger patient groups—but competition and clinical execution still matter.Read more

EnSilica builds custom chips for fast-growing markets like satellite internet and security, and recent deal activity in the sector suggests bigger players may pay up for the right technology and talent. The company says much of its future work is already lined up, but the path could still be bumpy if funding worries or customer timelines slip.Read more